Covidien launches 2 trials to support its Stellarex drug-device combo

Wed, 07/17/2013 - 9:58am
Mass Device

Covidien begins enrollment in a pair of clinical studies evaluating its Stellarex drug-coated angioplasty balloon in the U.S. and abroad.

Covidien launched 2 trials to support its Stellarex drug-device combo

Covidien (NYSE:COV) kicked off 2 new clinical trials this week to support a global evaluation of its Stellarex drug-coated angioplasty balloon.

The Massachusetts-based company started enrolling patients with peripheral arterial disease in the Pivotal and PK arms of its larger ILLUMENATE clinical trials examining the safety and effectiveness of Covidien's Stellarex devices.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.